




Parabolic Drugs Limited

Registered Office: SCO. 99 - 100, Top Floor, Sector - 17B, Chandigarh
Corporate Office: 9 AB, Taimoor Nagar, New Friends Colony, New Delhi
Unaudited Financial Results for the Half Year Ended 30th September, 2014

(Rs. Crores)

S.no.	Particulars	Three months	Preceding three	Corresponding	Six months	Corresponding	Previous
		Ended 30.09.2014	months ended 30.06.2014	Three months Ended 30.09.2013 in the previous year	Ended 30.09.2014	six months ended 30.09.2013 in the previous year	Accounting Year ended 31.03.2014
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Income from Operations						
	Gross Sales	53.30	113.63	119.23	166.93	217.05	446.71
	Less : Excise Duty	(3.67)	(3.99)	(5.32)	(7.66)	(6.79)	(16.33)
	(a) Net Sales/Income from Operations (Net of excise duty)	49.64	109.64	113.91	159.28	210.26	430.38
	(b) Other Operating Income	0.77	0.84	3.21	1.61	6.34	20.20
2	Total Income from Operations (net)	50.41	110.48	117.12	160.89	216.60	450.58
	Expenses						
	(a) Cost of Materials Consumed	39.77	95.67	105.81	135.44	198.43	390.62
	(b) Changes in inventories of finished goods, work-in-progress and stock-in-trade	0.40	-	(12.23)	0.40	(20.19)	(21.40)
	(c) Employee Benefits Expense	3.92	4.67	5.09	8.59	9.00	18.55
	(d) Depreciation & Amortisation Expense	17.26	17.23	16.99	34.49	34.03	68.08
	(e) Other Expenses (Any item exceeding 10% of the total expenses relating to continuing operations to be shown separately)	10.93	8.81	14.18	19.74	22.70	131.68
3	Total Expenses	72.28	126.38	129.84	198.66	243.97	587.53
	Profit/(Loss) from operations before Other Income, Finance Costs & Exceptional Items (1-2)	(21.88)	(15.90)	(12.72)	(37.77)	(27.37)	(136.95)
4	Other Income						
6	Profit/(Loss) from ordinary activities before finance costs and exceptional items (3 + 4)	(21.88)	(15.90)	(12.72)	(37.77)	(27.37)	(136.95)
7	Finance Costs	18.69	18.14	19.59	36.83	39.59	83.07
8	Profit/(Loss) from ordinary activities after finance costs but before exceptional items (5-6)	(40.57)	(34.04)	(32.31)	(74.60)	(66.96)	(220.02)
9	Exceptional Items						
10	Profit/(Loss) from Ordinary Activities before tax (7 + 8)	(40.57)	(34.04)	(32.31)	(74.60)	(66.96)	(220.02)
11	Tax expense	(12.53)	(10.52)	(9.99)	(23.05)	(20.69)	(61.30)
12	Net Profit/(Loss) from Ordinary Activities after tax (9 - 10)	(28.04)	(23.52)	(22.32)	(51.56)	(46.27)	(158.72)
13	Extra Ordinary Items (net of tax expense)						(26.98)
14	Net Profit / (Loss) for the period (11-12)	(28.04)	(23.52)	(22.32)	(51.56)	(46.27)	(131.74)
15	Share of Profit/(Loss) of Associates						
16	Minority Interest						
17	Net Profit/(Loss) after taxes, minority interest and share of profit/(loss) of Associates (13 + 14 + 15)	(28.04)	(23.52)	(22.32)	(51.56)	(46.27)	(131.74)
18	Paid-up equity share capital (Face Value of the Share shall be indicated) (Rs. 10/- each)	61.89	61.89	61.89	61.89	61.89	61.89
19 (i)	Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year						226.76
	Earnings Per Share (EPS) (before extraordinary items) - Shares of Rs. 10/- each (not annualised)						
	(a) Basic	(4.53)	(3.80)	(3.61)	(8.33)	(7.47)	(21.29)
	(b) Diluted	(4.53)	(3.80)	(3.61)	(8.33)	(7.47)	(21.29)
19 (ii)	Earnings Per Share (EPS) (after extraordinary items) - Shares of Rs. 10/- each (not annualised)						
	(a) Basic	(4.53)	(3.80)	(3.61)	(8.33)	(7.47)	(21.29)
	(b) Diluted	(4.53)	(3.80)	(3.61)	(8.33)	(7.47)	(21.29)
A.	PARTICULARS OF SHAREHOLDING						
1	Public Shareholding :						
	- Number of Shares	37,974,587	37,987,970	38,424,587	37,974,587	38,424,587	38182935
2	- Percentage of Shareholding	61.36	61.38	62.08	61.36	62.08	61.69
	Promoters and Promoter Group Shareholding :						
	(a) Pledged/Encumbered						
	- Number of shares	22,619,927	22,556,590	22,163,927	22,619,927	22,163,927	22372320
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	94.58	94.36	94.45	94.58	94.45	94.36
	- Percentage of shares (as a % of the total share capital of the company)	36.55	36.45	35.81	36.55	35.81	36.14
	(b) Non-Encumbered						
	- Number of shares	1,297,500	1,347,454	1,303,500	1,297,500	1,303,500	1336759
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	5.42	5.64	5.55	5.42	5.55	5.64
	- Percentage of shares (as a % of the total share capital of the company)	2.10	2.18	2.11	2.10	2.11	2.16



For Parabolic Drugs Limited

Authorised Signatory

B.	INVESTOR COMPLAINTS	Quarter ended 30/09/2014	Quarter ended 30/09/2013
	Pending at the beginning of the quarter	Nil	Nil
	Received during the quarter	3	Nil
	Disposed of during the quarter	3	Nil
	Remaining unresolved at the end of the quarter	Nil	Nil

	(Rs. Crores)	
	AS AT 30/09/2014 (Unaudited)	AS AT 31/03/2014 (Audited)
STATEMENT OF ASSETS AND LIABILITIES		
I. EQUITY AND LIABILITIES		
(1) Shareholder's Funds		
(a) Share Capital	61.89	61.89
(b) Reserves and Surplus	43.47	95.02
(2) Share Application Money Pending Allotment	26.00	26.00
(3) Non-Current Liabilities		
(a) Long-term borrowings	563.77	534.62
(b) Deferred tax liabilities (Net)	(127.92)	(104.87)
(c) Long term provisions	2.75	2.75
(4) Current Liabilities		
(a) Short-term borrowings	369.06	306.60
(b) Trade payables	131.63	189.20
(c) Other current liabilities	12.06	10.40
	1082.71	1121.61
II. ASSETS		
(1) Non-current assets		
(a) Fixed assets	410.30	412.24
(b) Non-current Investments	6.34	6.14
(c) Other non-current assets	114.87	137.62
(2) Current assets		
(a) Inventories	367.46	367.59
(b) Trade receivables	145.17	148.98
(c) Cash and cash equivalents	2.43	5.27
(d) Short-term loans and advances	30.52	40.01
(e) Other current assets	5.62	3.76
	1082.71	1121.61

Notes :

- The above quarterly results have been reviewed by the Audit Committee and taken on record by the Board of Directors in their meeting held on 14th November, 2014 and the same have been reviewed by the Statutory Auditors, as required under Clause 41 of the Listing Agreement.
- During the period under review, the company has incurred loss owing to the unfavourable market conditions, interest burden and economic stress, the company has witnessed an erosion in the margins of key products.
- The promoters' shareholding has been pledged pursuant to the terms of CDR package.
- There is not more than one reportable segment, hence, information as per AS-17 is not required to be disclosed.
- Figures of the previous year / period have been rearranged/regrouped wherever necessary.

Place : Chandigarh
Date : 14th Nov., 2014

For Parabolic Drugs Limited

Authorised Signatory

For Parabolic Drugs Ltd.

Pranav Gupta
Chairman & Managing Director

